Warning Letter — Sante Manufacturing Inc.
The FDA issued a Warning Letter to Sante Manufacturing Inc. on June 5, 2026, following an evaluation by the Center for Drug Evaluation and Research (CDER).
This affects Sante Manufacturing Inc., as well as personnel involved in drug manufacturing, quality systems, and regulatory filings for the company's product line.
The issuance of a Warning Letter by CDER suggests significant deviations from regulatory requirements, which may include Current Good Manufacturing Practice (CGMP) violations or unapproved drug status. While the source provides limited specific detail regarding the exact violations, such letters typically indicate that the firm's responses to previous inspectional observations were insufficient to demonstrate compliance.
Review manufacturing documentation and product labeling for adherence to current drug regulations. Ensure all facility registrations and product listings are current and accurate before seeking market entry or continuing distribution.
FDA Warning Letter issued to: Sante Manufacturing Inc.. 06/05/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/sante-manufacturing-inc-724931-06052026
Open in openFDA / FDA.gov